In add-on to eye dis­ease pipeline, Boehringer pays Sur­rozen to ac­quire rights to Wnt drug

Boehringer In­gel­heim wants in on Wnt, and it’s will­ing to cash out the big bucks if it pans out.

The deal was an­nounced by San Fran­cis­co’s Sur­rozen on Thurs­day morn­ing, where the biotech will be li­cens­ing a can­di­date, SZN-413, to Boehringer for reti­nal dis­eases.

Per the deal, Boehringer gets an ex­clu­sive and world­wide li­cense for not just the drug can­di­date, which is a bi-spe­cif­ic an­ti­body tar­get­ing a re­cep­tor called Fzd4. But it al­so lands two ad­di­tion­al back­ups, Sur­rozen CEO Craig Park­er tells End­points News, in ex­change for an up­front pay­ment of $12.5 mil­lion. Af­ter a cer­tain amount of undis­closed time work­ing to­geth­er, Boehringer In­gel­heim will take on all de­vel­op­ment and com­mer­cial re­spon­si­bil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER